Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Rating of “Hold” from Brokerages

Vir Biotechnology, Inc. (NASDAQ:VIRGet Rating) has earned an average rating of “Hold” from the eight analysts that are presently covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $73.83.

VIR has been the topic of several research reports. Needham & Company LLC dropped their price objective on shares of Vir Biotechnology from $80.00 to $45.00 and set a “buy” rating on the stock in a report on Monday, March 28th. Robert W. Baird raised shares of Vir Biotechnology from an “underperform” rating to a “neutral” rating and decreased their target price for the stock from $36.00 to $28.00 in a research report on Thursday, March 3rd. Zacks Investment Research raised shares of Vir Biotechnology from a “strong sell” rating to a “hold” rating in a research report on Friday. HC Wainwright reissued a “buy” rating and set a $200.00 target price on shares of Vir Biotechnology in a research report on Monday, May 2nd. Finally, TheStreet downgraded shares of Vir Biotechnology from a “c-” rating to a “d+” rating in a research report on Monday, March 28th.

VIR stock opened at $20.62 on Tuesday. The company’s fifty day simple moving average is $23.14 and its 200 day simple moving average is $31.90. Vir Biotechnology has a 12-month low of $19.44 and a 12-month high of $58.00. The firm has a market cap of $2.73 billion, a price-to-earnings ratio of 2.28, a PEG ratio of 0.42 and a beta of -0.55.

Vir Biotechnology (NASDAQ:VIRGet Rating) last announced its quarterly earnings data on Thursday, May 5th. The company reported $3.85 earnings per share for the quarter, beating the consensus estimate of $3.78 by $0.07. Vir Biotechnology had a net margin of 52.29% and a return on equity of 119.80%. The firm had revenue of $1.20 billion for the quarter, compared to analyst estimates of $811.05 million. During the same quarter in the prior year, the business earned ($1.32) earnings per share. The business’s quarterly revenue was up 59900.0% compared to the same quarter last year. Equities analysts anticipate that Vir Biotechnology will post 4.64 earnings per share for the current year.

In other Vir Biotechnology news, EVP Herbert Virgin sold 1,375 shares of the business’s stock in a transaction dated Tuesday, February 22nd. The shares were sold at an average price of $30.00, for a total value of $41,250.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Vicki L. Sato sold 17,915 shares of the business’s stock in a transaction dated Thursday, April 28th. The shares were sold at an average price of $20.90, for a total transaction of $374,423.50. Following the completion of the transaction, the director now owns 1,518,004 shares in the company, valued at $31,726,283.60. The disclosure for this sale can be found here. Insiders sold a total of 41,627 shares of company stock valued at $1,111,996 over the last ninety days. 22.40% of the stock is currently owned by insiders.

Several hedge funds have recently made changes to their positions in the stock. Point72 Asset Management L.P. increased its holdings in shares of Vir Biotechnology by 9,370.5% in the 4th quarter. Point72 Asset Management L.P. now owns 2,055,100 shares of the company’s stock worth $86,047,000 after buying an additional 2,033,400 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Vir Biotechnology by 485.9% in the 4th quarter. Millennium Management LLC now owns 967,825 shares of the company’s stock worth $40,523,000 after buying an additional 802,652 shares during the last quarter. Norges Bank bought a new position in shares of Vir Biotechnology in the 4th quarter worth $20,827,000. Alliancebernstein L.P. increased its holdings in shares of Vir Biotechnology by 22.6% in the 4th quarter. Alliancebernstein L.P. now owns 2,620,753 shares of the company’s stock worth $109,731,000 after buying an additional 483,261 shares during the last quarter. Finally, Qube Research & Technologies Ltd bought a new position in shares of Vir Biotechnology in the 1st quarter worth $8,460,000. Institutional investors own 79.91% of the company’s stock.

Vir Biotechnology Company Profile (Get Rating)

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.

See Also

Analyst Recommendations for Vir Biotechnology (NASDAQ:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.